Five9 Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN RAMON, Calif.--(BUSINESS WIRE)-- Five9, Inc. (Nasdaq: FIVN) (“Five9” or the “Company”) today announced that on August 13, 2026, the Company granted a restricted stock unit award (the “RSU”) covering 26,982 Shares to Sarah Bennett (the “Inducement Award”). The Compensation Committee of the Board of Directors of the Company approved the grant of the Inducement Award, which was offered as a material inducement to Ms. Bennett entering into employment with the Company, as the Vice President, Revenue Strategy & Operations, effective as of July 20, 2026. The Inducement Award was granted under the Five9, Inc. 2026 Inducement Equity Incentive Plan. 1/3 of the RSUs will vest on September 3, 2027, and 1/12 of the RSUs will vest quarterly thereafter, so that the RSUs are fully vested on September 3, 2029, subject to the employee’s continuous service through the applicable vesting date.

The award was granted in reliance on the employment inducement exemption under the Nasdaq Stock Market Listing Rule 5635(c)(4), which requires public announcement of inducement awards. The Company is issuing this press release pursuant to Listing Rule 5635(c)(4).

About Five9

Five9 empowers organizations to create hyper-personalized and effortless AI-driven customer experiences that deliver better business outcomes. Powered by Five9 Genius AI, the Five9 Intelligent CX Platform is trusted by 3,000+ customers and 1,400+ partners globally. The New CX starts here, and it’s at the heart of every winning experience. For more information, visit www.five9.com.

Engage with us @Five9, LinkedIn, Facebook, Blog

View source version on businesswire.com: https://www.businesswire.com/news/home/20260818731281/en/

Investor Contact:
Tony Righetti
SVP, Investor Relations
[email protected]

Source: Five9, Inc.

You May Also Be Interested In

• Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
• CTP N.V. Capital Markets Day Showcases Record Leasing and Self-funded Expansion Model
• [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity